• Japanese
  • Korean
  • Chinese
Cover Image

Molecular Diagnostics

This report analyzes the worldwide markets for Molecular Diagnostics in US$ Thousands by the following Applications: Infectious Disease Testing, Blood Screening, Cancer Screening, and Other Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 165 companies including many key and niche players such as -

Abbott Laboratories
Becton, Dickinson and Company
bioMerieux SA
Cepheid
CytoCore Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. OUTLOOK

  • Molecular Diagnostics - A Prelude
  • Current and Future Analysis
  • US and Europe - Leaders in Molecular Diagnostics Adoption
  • Developing Countries Excel in Growth Prospects
  • Major Growth Drivers
  • Key Market Trends in a Nutshell
  • Major Technology Trends
  • Major Issues and Challenges
  • The Future in Store

2. MEDICAL DIAGNOSTICS MARKET - A REVIEW

  • Clinical Diagnostics Industry - Trends and Tendencies
  • Global In-Vitro Diagnostics (IVD) Market: A Prelude
    • Table 1: Global In Vitro Diagnostics Market by Leading Players (2013): Percentage Share Breakdown of Revenues for Abbott Laboratories, bioMerieux, Danaher, J&J, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart)
    • Table 2: Global In-Vitro Diagnostics Market by Segment (2013): Percentage Breakdown of Value Sales for Hematology, Hemostasis, Immunochemistry, Microbiology, Molecular Diagnostics, Point-of-Care Diagnostics, Self-Monitoring Blood Glucose, and Tissue Diagnostics (includes corresponding Graph/Chart)
    • Table 3: Global In-Vitro Diagnostics Market by Sector (2013): Percentage Breakdown of Revenues for Decentralized & Patient Self-Testing and Hospital & Commercial Laboratories (includes corresponding Graph/Chart)
  • Classification of Diagnostic Tests
  • Molecular Diagnostics - A Replacement and Enabling Technology
  • Advancements in Molecular Diagnostics - A Boon for the Industry
  • Nucleic Acid Diagnostics Market - An Overview

3. MOLECULAR DIAGNOSTICS INDUSTRY - AN OVERVIEW

  • Molecular Diagnostics - A Rapidly Advancing Market
  • Molecular Diagnostics: Marking the Convergence of Numerous Technologies
  • Towards Tailoring the Right Treatment for the Right Disease
  • Business Opportunities in the Offing
  • Improving Healthcare Expenditure Turbo Charges Demand
    • Table 4: Per-Capita Healthcare Expenditure in Select Regions (2013) (includes corresponding Graph/Chart)
    • Table 5: Top 20 Countries with the Highest Healthcare Spending as a Percentage of GDP (2012) (includes corresponding Graph/Chart)
    • Table 6: Top 10 Countries with Highest Private Spending on Health Care (2011) (includes corresponding Graph/Chart)
  • Demographics Spell Growth Opportunities
    • Table 7: Global Population Statistics for the 65+ Age Group (2013) (includes corresponding Graph/Chart)
    • Table 8: Elderly Population (60+ Years) as a Percentage of the Total Population (2012 & 2050) (includes corresponding Graph/Chart)
    • Table 9: Global Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 10: Aging Population by Age Group in More Developed Countries (1975-2050) (includes corresponding Graph/Chart)
    • Table 11: Aging Population by Age Group in Less Developed Countries (1975-2050) (includes corresponding Graph/Chart)
    • Table 12: Aging Population by Age Group in Least Developed Countries (1975-2050) (includes corresponding Graph/Chart)
    • Table 13: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
  • Technological Innovations Set to Drive the Market
  • The Role of Molecular Diagnostics in Personalized Medicine
  • Companion Diagnostics Make Way for Personalized Medicine
    • List of Select FDA-Cleared Companion Diagnostic Devices
  • Biomarkers as Companion Diagnostics
  • Proteomics Technologies: Growing in Significance
  • New Developments in Proteomics Technologies
  • New Applications Hold Promising Potential
  • Molecular Diagnostics for Lymphoid Malignancies
  • Next-Generation Sequencing Technologies Keep Up the Momentum
  • Select Commercial NGS Technologies
  • Select Promising NGS Technologies in Development (As of 2012)
  • Rising Emphasis on Lab Automation to Augur Well for Market Growth
  • List of Fully Automated and Rapid Molecular Diagnostics
  • Molecular Diagnostics and Intellectual Property
  • Medical Training and Practice Challenges
  • The Enlightened Consumer of the 21st Century
  • Information Handling & Processing: The Soft Side of Diagnostics
  • Hurdles All the Way for Companies Eyeing Molecular Diagnostics
  • Molecular Diagnostics - Moving from Centralization to Decentralization
  • Migrating to Decentralized Format
  • Going Ahead with Decentralization
  • Limited Reimbursements by Third Party Payers - A Stumbling Block

4. AN INSIGHT INTO APPLICATIONS OF MOLECULAR DIAGNOSTICS

  • Infectious Diseases Molecular Testing
  • Overview
    • Activity in the Field
    • Identifying Multidrug Resistance
    • Infectious Disease Treatment Monitoring
    • Other Infectious Diseases Applications
  • Key Trends
    • Increasing Incidence of Infectious Diseases Fuel Adoption
    • Table 14: Reported Cases of Major Infections by Select Geographic Region: 2011
    • Rising Incidence of Hospital Acquired Infections Propels Market Growth
      • Comparison of Different Parameters for Select C. diff MDx Tests
    • Rising HIV Prevalence Provides Ample Growth Opportunities
    • Table 15: Global Prevalence of HIV Infection in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
    • Table 16: Newly Infected HIV Population in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
    • Table 17: Global HIV Related Deaths in 2012 by Region (in Millions) (includes corresponding Graph/Chart)
    • Table 18: Top Twelve Countries in APAC with The Highest HIV Incidence (2012) (includes corresponding Graph/Chart)
    • Infectious Disease Testing - A Major Driver of Molecular Diagnostics Market
      • Select FDA-Cleared Molecular Diagnostic Tests for Infectious Diseases
    • Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
    • Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
    • HPV Testing: A Fast Growing Segment in the Molecular Diagnostic Testing Market
      • List of Select HPV Molecular Diagnostic Tests by Company and Technique
    • Archaic TB Diagnostic Methods Opens Up Opportunities for Molecular Diagnostics
      • List of Select Commercially-Available TB Diagnostics
      • An Overview of Select TB Diagnostics under Development
    • Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential...
    • PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
  • Blood Screening
  • Molecular based Tests Ingrain Roots in Blood Donor Screening Segment
  • Cancer Screening & Diagnosis
  • Overview
  • Molecular Tests Lead the Way for Cancer IVD Market Growth
  • Molecular Markers to Enhance Thyroid Cancer Diagnosis
  • Oncology-Based Molecular Diagnostics: The Propitious Segment
    • List of US-FDA Approved Biomarkers for Cancer
    • Table 19: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & The Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 20: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart)
    • Table 21: Medical Costs Associated with Cancer by Affected Site: 2010 (includes corresponding Graph/Chart)
  • Growing Popularity of Chemo-Sensitivity Testing of CTCs
  • Cervical Cancer Screening: Focus on Detection of CIN2 and CIN3 Cancers
  • Other Testing Applications
  • Genetic Disease Testing Applications
    • Overview
    • Pharmacogenomics - Prognosis Based on Genomics
    • Pharmacogenomics Development Augurs Growth of Genetic Testing Market
    • Prospects for Genetic Diagnostics and Testing Grow Brighter
      • List of Select FDA-Cleared Genetic Tests by Disease
    • Genetic Testing - An Indispensible Tool for Cystic Fibrosis
    • Table 22: Most Common Mutations and Worldwide Frequency (includes corresponding Graph/Chart)
    • Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions
    • Non-Invasive Prenatal Diagnostics - The Way Ahead
    • Nucleic Acid Amplification Methods for Detection of Antimicrobial Resistance
      • PCR-Based Nucleic Acid Amplification for Detection of Antimicrobial Agents
    • Histocompatibility Testing
    • Table 23: Global HLA Testing Market (2012-2016E): Revenue Estimates for 2012 through 2016 (includes corresponding Graph/Chart)

5. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET

  • Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market
  • An Overview of Competitive Landscape in Molecular Diagnostics
    • Table 24: Leading Players in the Global Molecular Diagnostics Market (2012): Percentage Share Breakdown by Value Sales for Abbott, Becton, Dickinson & Company, bioMerieux, Cepheid, Hologic/Gen-Probe, Novartis, Qiagen, Roche Diagnostics, Siemens and Others (includes corresponding Graph/Chart)
  • Other Noteworthy Companies and their Competitive Position by Segment
  • Key Players and Their Technologies
    • The Top Tier
    • Mid-Sized and Small Companies
  • Cepheid: Unquestioned Leader in the Rapid and Automated MDx Market
    • Price Comparison of Select Fully Automated and Rapid Molecular Diagnostics
  • Qiagen: The Leading Player in the Global HPV MDx Market
    • Comparative Analysis of Select HPV MDx Tests
  • Competitive Dynamics in the C. difficile Testing Market
    • Table 25: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2013): Percentage Breakdown of Revenues for Becton Dickinson, Cepheid, Meridian and Others (includes corresponding Graph/Chart)
    • List of Select Molecular C. difficile Test Products
  • Competition in the Blood Screening MDx Market
    • Table 26: Global Blood Screening MDx Market by Leading Players (2013): Percentage Market Share Breakdown of Value Sales for Hologic Gen-Probe, Roche and Others (includes corresponding Graph/Chart)
  • Competitive Landscape in the Global RT-PCR Market
    • Table 27: Leading Players in Global RT-PCR Instruments Market (2012): Percentage Breakdown of Value Sales for Life Sciences Research by Leading Players - Life Technologies, Bio-Rad, Roche, Agilent, Qiagen and Others (includes corresponding Graph/Chart)
    • Select Real-Time PCR Products by Company
  • Competition Heats Up in dPCR Market
    • Table 28: Leading dPCR Systems At a Glance
  • Life Sciences Companies Eye on Lucrative Prostate Cancer MDx Market
  • Consolidation Activity Continues to Strengthen Driven by New Entrants
    • Major M&A Transactions in Molecular Diagnostics: 2011-2014
    • New Entrants in Molecular Diagnostics Landscape: 2010-2013
    • Some Examples of Recent Transactions by New Entrants in the MDx Market
  • Product Marketing - Key to Commercial Success

6. PRODUCT & TECHNOLOGY OVERVIEW

  • Molecular Diagnostics - Definition & Scope
  • Molecular Diagnostics - Impact on Healthcare
  • Utility of Molecular Diagnostic Tests
  • Background of Molecular Diagnostics
  • Major Milestones in the Evolution of Molecular Diagnostics
  • Types of Molecular Diagnostics
  • Conventional Diagnostics Vs. Molecular Diagnostics
  • Unabated Developments in Molecular Diagnostics Technology
  • Signal Amplification Technologies
    • PCR - New Developments
    • Quantitative Real-Time PCR for Molecular Diagnostics
    • Signal Detection and Quantification
    • Quantitative Real-Time RT-PCR Analysis
      • Applications of Quantitative Real-Time PCR Analysis
    • Digital PCR
    • Non-PCR Methods
    • Other Signal Amplification Technologies
  • DNA Probe Based Products
    • Direct Detection of Specific Nucleic Acid Sequences
    • Nucleic Acid Amplification and Detection
    • DNA Sequencing and Gene Detection
    • Arrays of Immobilized Probes (DNA Chips) in Gene Detection
  • RNA Diagnostics
  • Complementary Molecular Diagnostic Technologies
    • Fluorescent In-Situ Hybridization (FISH)
    • DNA Biochips/Microarrays
    • Biosensors
    • Proteomic Technologies for Molecular Diagnostics
    • Nanotechnology for Molecular Diagnostics
  • Technologies on the Anvil
    • Haplotype Analysis - A Distant Possibility
    • Chronic Multi-Gene Defects Now Diagnosable
  • Whole Genome Sequencing - Boon or Bane to Genetic Testing

7. PRODUCT APPROVALS/INTRODUCTIONS

  • Grifols Obtains CE-Marking for ID CORE XT Molecular Diagnostic Kit
  • QIAGEN Rolls Out careHPV(tm) Test in India
  • QIAGEN Gets PMA Approval from the US FDA for artus(r) CMV RGQ MDx Kit
  • Alere Obtains FDA Approval for Alere(tm) i Influenza A and B Test
  • Qiagen Obtains Approval from the US Health Regulators for Gene-Testing Kit
  • Immucor Obtains the US FDA Approval for PreciseType HEA Test
  • bioMerieux Obtains PMA Approval from the FDA for THxID(tm)-BRAF Companion Diagnostic Test
  • Cepheid Obtains FDA Clearance for Xpert(r) MTB/RIF Test
  • Roche Gains FDA 510(k) Approval to use Four Additional Specimens with Cobas Ct/Ng V2.0 Test
  • PrimeraDx Gains FDA 510(k) Clearance for ICEPlex System
  • Illumina Receives FDA Premarket Approval for Miseqdx System
  • Hologic Obtains Health Canada Approval for Aptima HPV Assay
  • Life Technologies Obtains NDIS Approval for GlobalFiler Express Kit
  • Serascience Obtains CE Mark Approval for Seralite(r)
  • IntelligentMDx Obtains US FDA Approval for Automated Molecular Diagnostic Test
  • Meridian Bioscience Obtains FDA Approval for illumigene(r) Mycoplasma
  • IntelligentMDx Obtains CE-Mark Approval for IMDx Flu A/B and RSV Test
  • BD Diagnostics Obtains FDA Approval for BD MAX(tm) Cdiff Assay
  • Quidel Obtains 510(k) Approval for Quidel Molecular RSV + hMPV Assay
  • Roche Seeks FDA Approval for Cervical Cancer Primary Screening Indication for the Cobas(r) Hpv Test
  • Quidel Gets FDA Nod for New Molecular Diagnostic Tests
  • Abbott Launches RealTime Molecular Test for HPV
  • Diagnovus Introduces ENGAUGE(tm)-Cancer DLBCL Gene Panel
  • Roche Introduces Cobas p 480 Instrument
  • LabCorp Launches BRCAssureSM Breast Cancer Mutation Tests
  • Cytocell Introduces Cytocell CLL FISH Probes
  • Cancer Genetics Introduces FHACT(tm) DNA-Based Cervical Cancer Diagnostic Test
  • Abbott Releases IMDx C.difficile Test
  • Myriad Genetics Introduces myPath(tm) Melanoma Molecular Diagnostic Test
  • Biocartis Develops New MDx Prototype Platform
  • BioChain Collaborates with Epigenomics to Introduce Septin9 IVD Test
  • Advanced Cell Diagnostics and Kindstar Partner to Introduce New Molecular Diagnostic Assays
  • EKF Diagnostics Introduces Four New PointMan(tm) DNA Enrichment Kits
  • DiaCarta Introduces QClamp(tm) Somatic Mutation Real-Time PCR Tests
  • Biocartis to Launch Idylla Molecular Diagnostic Platform
  • Personalis Launches the ACE Clinical Exome(tm)
  • Roche to Launch Cobas 6800 and Cobas 8800 MOLECULAR Dx Systems
  • Illumina Launches TruSight One Sequencing Panel
  • Abbott Laboratories Releases New FDA-Approved Molecular Diagnostic Flu A/B and RSV Test
  • Natural Molecular Testing Releases New Diagnostic Molecular Tests for Women
  • DiaSorin's Molecular Division Launches Iam Toxo Assay for T. gondii Detection
  • Myriad Genetics Introduces myRisk(tm) Hereditary Cancer Panel
  • BD Diagnostics Launches FDA-Cleared BD ProbeTec(tm) Trichomonas Vaginalis Qx Amplified DNA Assay
  • ELITechGroup Molecular Diagnostics Introduces ELITe STAR
  • Assurex Health Launches GeneSight Psychotropic 2.0
  • Theradiag Rolls Out two new Multiplexed Molecular Diagnostic Assays
  • Bioline Releases the MyTaq(tm) Extract-PCR Kit
  • HTG Rolls Out HTG Edge DMPK Assay and HTG Edge TOA Assay
  • BD Diagnostics Introduces Real-Time PCR Kit for Diagenode Bordetella Pertussis/Parapertussis Detection
  • Abbott Launches Real-time HCV Genotype II Test
  • Abbott Introduces FDA-Approved Real-Time HCV Genotyping Test Assay
  • DiaSorin Releases New IAM PARVO Molecular Diagnostic Test for Parvo Virus Detection
  • GeneDx to Introduce Comprehensive Breast Cancer Genetic Tests
  • Vela Diagnostics Develops New PCR-based Assays Targeting the H7N9 Bird Flu Strain
  • Cancer Genetics Introduces UroGenRA(tm) Urogenital Cancer Array
  • Bioline Releases ISOLATE II Nucleic Acid Purification Kits
  • MLabs Announces Commercial Availability of MiPS Test for Prostate Cancer
  • Cancer Genetics Introduces New Genetic Test for Cervical Cancer Management
  • Knight Diagnostic Laboratories Launches GeneTrails Cancer Tests
  • Integrated Diagnostics Releases Xpresys(tm) Lung Blood Test
  • Seegene Unveils Real-Time Array Technology for POC Testing
  • Medical Diagnostic Laboratories Releases New Azithromycin Resistance Reflex Assay for Chlamydia Trachomatis
  • BD Diagnostics Introduces New Molecular Test
  • Nanosphere Receives FDA Authorization for Marketing BC-GP Test
  • Abbott Secures CE Marking for PLEX-ID(tm) System and Clinical Assays

8. RECENT INDUSTRY ACTIVITY

  • Thermo Fisher Scientific Acquires Life Technologies
  • Myriad Genetics Takes Over Crescendo Bioscience
  • AUT University Collaborates with Roche Diagnostics
  • Corgenix Medical Obtains NIH Grant to Advance Development of Ebola Rapid Diagnostic Test Kit
  • Cepheid Collaborates with AstraZeneca, Cubist Pharmaceuticals and GSK
  • B Braun US and CeGaT Join Forces to Establish B Braun CeGaT
  • Provista Diagnostics Expands Exclusive License Agreement for Certain Biomarker and Autoantibody Technologies
  • Veracyte and Fleury Partner to Offer the Afirma(r) Gene Expression Classifier
  • Integrated Diagnostics Attracts Financing for Xpresys Lung Molecular Diagnostic Blood Test
  • MDxHealth Enters into Agreement with Galaxy Health
  • QIAGEN Acquires Exclusive Worldwide License to CALR Biomarker
  • Zyomyx Obtains $7.5 Million from UNITAID to Launch MyT4(tm) POC CD4 Test
  • Human Longevity Inc. Commences its Operations
  • Roche Takes Over IQuum
  • Myriad Genetics and Sividon Diagnostics Ink Exclusive Co-Marketing Agreement
  • Grifols to Acquire Transfusion Diagnostics Unit of NOVARTIS Diagnostics
  • Life Technologies and Advanced Cell Diagnostics Enter into Global Distribution Agreement
  • Microbiologics Acquires Phthisis Diagnostics
  • bioMerieux Enters into Agreement to Acquire BioFire Diagnostics
  • Response Genetics Takes Over Substantial Assets of Pathwork Diagnostics
  • Mobidiag, Genewave and Amplidiag Merge
  • EKF Diagnostics Holdings Established New Subsidiary
  • Cynvenio and CollabRx Collaborate for Cancer Molecular Diagnostics
  • bioTheranostics Inks Collaboration Agreement with Mayo Clinic and Mayo Medical Laboratories
  • bioMerieux Terminates Collaboration with Biocartis in Molecular Biology Field
  • Rosetta Genomics Expands Distribution Agreement with GeneKor for microRNA Cancer Testing Services
  • QIAGEN Enters into an Agreement with Eli Lilly
  • Transgenomic Collaborates with PerkinElmer
  • Diagnoplex and Unilabs Ink Collaboration Agreement to Commercialize Colox
  • Pacific Edge Inks Agreement with FedMed
  • PDI and Transgenomic Sign Long-Term Collaboration Agreement for CardioPredict(tm) Molecular Diagnostic Test
  • HiberGene Obtains US Patent Rights for Molecular Diagnostic Test for Meningococcus
  • OncoDNA Signs Collaboration Agreement with IBBL
  • MDxHealth Collaborates with HistoGeneX
  • Co-Diagnostics Partners with DNA Logix to Form Infectious Disease Dx Joint Venture
  • Lumora and Promega Sign Supply Agreement for Ultra-Glo(tm) Luciferase
  • MDxHealth Enters into Partnership with Summit Pharmaceuticals
  • Myriad Genetic Enters into Agreement with TESARO
  • Cancer Genetics Enters into Distribution Agreement with Excilone
  • Cancer Genetics Italia Enters into Agreement with Nikon Instruments
  • CollabRx and OncoDNA Enter into Long-Agreement to Buy CollabRx SaaS-based Technology and Content Resources
  • CollabRx Enters into Partnership with Sengenics for Molecular Diagnostics
  • Diasorin Enters into Agreement with Seegene
  • Cancer Genetics Appoints Cytogen and Cytogen Polska as Distributors for CGI Italia DNA-FISH Probes
  • FDA Re-Categorizes Meridian Bioscience's illumigene(r) Group A Streptococcus and illumigene(r) Group B Streptococcus Tests
  • Kreatech Signs Agreement with LCMC
  • HiberGene Diagnostics Commences Manufacturing Process for Meningococcus MDx Test
  • SYGNIS Pharma to Foray into Molecular Diagnostics Products Business
  • IntelligentMDx Signs Long-Term Agreement with QIAGEN
  • The Icahn School of Medicine Collaborates with Exosome Diagnostics
  • Tianjin Cancer Hospital Joins Forces with Tektronix
  • Maverix Biomics Enters into Co-Marketing Agreement with QIAGEN
  • CollabRx Enters into Multi-Year Agreement with Quest Diagnostics
  • Personal Genome Diagnostics Collaborates with MolecularMD
  • Applied Proteomics Collaborates with the German Cancer Research Center
  • Diagnoplex and Unilabs Ink Collaboration Agreement
  • CombiMatrix Enters into Strategic Alliance with Manhattan Labs
  • MRIGlobal and Evogen Ink Agreement for Molecular Diagnostics Products Development
  • Rheonix Signs Joint Development Agreement with Life Technologies
  • Qiagen Collaborates with Exosome Diagnostics
  • Diaxonhit and XDx Sign Definitive Exclusive License and Distribution Agreement
  • Genewiz Enters into Partnership with Chinese KeyTest Diagnostics
  • IncellDx Inks Agreement with GeneCell Diagnostics
  • PrimeraDx Enters into Agreement with Quest Diagnostics to Co-Develop Companion Diagnostics
  • Evogen Inks Licensing Agreement with Focus Diagnostics
  • Lpath Enters into Collaboration and License Agreement with Provista
  • Lab21 Inks Agreement with IntegraGen
  • Analytik Jena Acquires SIRS-Lab
  • Swift Biosciences Enters into Licensing Agreement with Vela Operations
  • BioFire Secures $25 Million Fund from Athyrium

9. FOCUS ON SELECT PLAYERS

  • Abbott Laboratories (US)
  • Abbott Molecular, Inc. (US)
  • Becton, Dickinson and Company (US)
  • bioMerieux SA (France)
  • Cepheid (US)
  • CytoCore Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GE Healthcare (US)
  • Grifols International, S.A. (Spain)
  • Hologic, Inc. (US)
  • Hologic Gen-Probe Incorporated (US)
  • QIAGEN N.V. (The Netherlands)
  • Quest Diagnostics, Inc. (US)
  • Celera Corp. (US)
  • Siemens AG (Germany)
  • Tecan Group Ltd. (Switzerland)
  • The ELITechGroup SAS (France)
  • Thermo Fisher Scientific (US)

10. GLOBAL MARKET PERSPECTIVE

    • Table 29: World Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 30: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 31: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
  • Molecular Diagnostics Market by Application
    • Table 32: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 33: World Historic Review for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 34: World 15-Year Perspective for Molecular Diagnostics in Infectious Disease Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 35: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 36: World Historic Review for Molecular Diagnostics in Blood Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 37: World 15-Year Perspective for Molecular Diagnostics in Blood Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 38: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 39: World Historic Review for Molecular Diagnostics in Cancer Screening by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 40: World 15-Year Perspective for Molecular Diagnostics in Cancer Screening by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 41: World Recent Past, Current & Future Analysis for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 42: World Historic Review for Molecular Diagnostics in Other Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 43: World 15-Year Perspective for Molecular Diagnostics in Other Applications by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Molecular Diagnostics Maintain its Positive Momentum
      • A Glance at Major Growth Drivers
      • Key Challenges Facing the MDx Market
    • qPCR and dPCR Instrumentation in the US: An Overview
    • Ageing Demographics: Major Driving Factor
    • Table 44: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 45: US Population Breakdown by Age Group: 2012 (includes corresponding Graph/Chart)
    • Increasing Burden of Chronic Diseases Drives Focus onto Molecular Diagnostics
    • US Individualized Medicine Market to Witness Significant Growth
    • Companion Diagnostic Market in the US
      • List of Select FDA-Cleared Companion Diagnostics
      • Number of Companion Diagnostics under Development Keeps Soaring
    • Burgeoning Potential for Genetic Testing
      • Direct-to-Consumer Testing - A Growing Market
    • Epidemic Proportion of Cancer in the US - Key Driver for Cancer Genetic Testing
    • Table 46: New Cancer Cases by Gender and Affected Site in the US (2013)
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
      • List of FDA-Cleared CF MDx Tests
    • Table 47: CF Carrier Screening in the US (2012): Percentage Breakdown of Population by Coverage Policy (includes corresponding Graph/Chart)
    • Table 48: CF Diagnostic Testing in the US (2012): Percentage Breakdown of Population by Coverage Policy (includes corresponding Graph/Chart)
    • Molecular Diagnostics Tests Gaining Share in STD Testing Domain
    • HPV Testing Market - A Review
    • Table 49: Cervical Cancer by HPV Type in the US (2012): Percentage Share Breakdown of Cervical Cancer Cases by HPV Type (includes corresponding Graph/Chart)
      • Competitive Landscape
    • Table 50: Leading Players in the US HPV Testing Market (2010 & 2011): Percentage Share Breakdown of Number of Tests for QIAGEN, Hologic, and Roche (includes corresponding Graph/Chart)
      • List of FDA Approved HPV MDx Tests
    • Regulatory Environment
      • FDA Regulations
      • Clinical Laboratory Improvement Amendments (CLIA)
    • Table 51: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Laboratories by Certificate Type (includes corresponding Graph/Chart)
    • Table 52: CLIA-Certified Laboratories in the US (2013): Percentage Share Breakdown of Number of Labs by Lab Type (includes corresponding Graph/Chart)
      • Genetic Testing
      • FDA to Implement Strict Measures for Cervical Cancer Screening Tests
      • Limited Reimbursements - A Major Hindrance
      • New MoPath Codes for Reimbursement for Molecular Diagnostics Tests
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 53: US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 54: US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 55: US 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • A Statistical Review of Cancer Incidence in Canada
    • Table 56: New Cancer Cases in Canada by Gender and Affected Site: 2012 (includes corresponding Graph/Chart)
    • Table 57: New Cancer Cases in Canada by Province: 2012 (includes corresponding Graph/Chart)
    • Product Approval
  • B. Market Analytics
    • Table 58: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 59: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 60: Canadian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Demographics Drive Market Growth
    • Table 61: Percentage Breakdown of Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)
    • Table 62: Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 63: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 64: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 65: Japanese 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Debt Crisis in Europe Affects Healthcare Industry
    • European Healthcare System: In a State of Transition
    • Insight into Molecular Diagnostics Markets in Europe
    • Table 66: Molecular Diagnostics Tests: Percentage Share Breakdown by Function (includes corresponding Graph/Chart)
    • Increasing Testing Needs of the Elderly: Business Case for Molecular Diagnostics
    • Table 67: Population Breakup by Age Group for Select European Countries: 2012 (As a % of Total Population) (includes corresponding Graph/Chart)
    • PCR Reagents in Europe: An Overview
    • Automated Systems Gain Preeminence
    • Oncology-based Molecular Diagnostics Holds Immense Potential
    • European Personalized Medicine Market to Exhibit Robust Growth
    • HPV Testing in Europe: An Overview
      • List of Select CE-Marked HPV Molecular Diagnostic Tests
    • Table 68: Cervical Cancer Incidence and Mortality in European Countries (2012)
    • Table 69: Prevalence of Cervical Cancer in European Countries (2012)
    • Table 70: European HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart)
    • Regulatory Scenario in Europe for Companion Diagnostics
      • Select European Players with Strong Biomarker Pipeline in Companion Diagnostics
    • Product Approvals/Launches
  • B. Market Analytics
    • Table 71: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 72: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 73: European 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 74: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 75: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 76: European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 77: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 78: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 79: French 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current and Future Analysis
    • Overview
    • Strategic Corporate Developments
    • Siemens AG - A Key Player
  • B. Market Analytics
    • Table 80: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 81: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 82: German 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launches
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 83: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 84: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 85: Italian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • SMIP for Pharmacogenomic Testing
    • Product Launches
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 86: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 87: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 88: The UK 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current and Future Analysis
    • Spain - Poised to become a Reckoning Force in Personalized Medicines
    • Strategic Corporate Development
    • Grifols International, S.A. - A Key Player
  • B. Market Analytics
    • Table 89: Spanish Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 90: Spanish Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 91: Spanish 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 92: Russian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 93: Russian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 94: Russian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launches/Approvals
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 95: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 96: Rest of European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 97: Rest of European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Healthcare Spending in Asia-Pacific: On the Rise
    • In-vitro Diagnostics Market: India & China Offer Significant Growth Opportunities
    • Table 98: China and India Leads Global Population (July 2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart)
    • Table 99: Age-wise Breakup of China and India's Population Vis-a-vis Other Populous Countries Globally: As of July 2013 (includes corresponding Graph/Chart)
    • Molecular Diagnostics Testing Opens New World of Possibilities
    • Recent Advancements in Molecular Diagnostics Market: A Quick Review
      • Novel Genetic Testing Methods
      • Development of Personalized Healthcare Approaches
      • Molecular Painting for Genetic Diagnosis of Diseases
      • New Technique to Detect H1N1 Virus
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 100: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 101: Asia-Pacific Historic Review for Molecular Diagnostics by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 102: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Revenues for China and Rest of Asia-Pacific Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
    • Table 103: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 104: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 105: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current and Future Analysis
    • In-Vitro Diagnostics Market on the Growth Curve
    • HPV Testing in China: An Overview
    • Government Support Drives Personalized Medicine Market in China
    • Product Launches
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 106: Chinese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 107: Chinese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 108: Chinese 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

5b. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • A Focus on the Indian Molecular Diagnostics Market
      • Molecular Diagnostic Market in India to Witness Significant Growth
      • Growth Drivers in a Nut Shell
      • Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
      • Indian Scientific Research towards Functional Genomics and Proteomics
      • Automation - The Emerging Trend in IVD Industry
      • Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
      • HPV Testing Market: An Overview
    • Table 109: HPV in India - Breakdown of Type-Distribution and HPV Prevalence (includes corresponding Graph/Chart)
    • Product Launches/Approvals
  • B. Market Analytics
    • Table 110: Rest of Asia Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 111: Rest of Asia Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 112: Rest of Asia Pacific 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Current and Future Analysis
    • Brazilian IVD Market on the Rise
  • B. Market Analytics
    • Table 113: Latin American Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 114: Latin American Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 115: Latin American 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launch
  • B. Market Analytics
    • Table 116: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 117: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 118: Rest of World 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Revenues for Infectious Disease Testing, Blood Screening, Cancer Screening and Other Applications Markets for Years 2006, 2014 and 2020 (includes corresponding Graph/Chart)
Show More
RELATED REPORTS
* 2014-2018 European Infectious Disease Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
  • Published:
  • Nov 12, 2014
  • USD 7700
  • 700 Pages

* 2014-2018 European Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing
  • Published:
  • Nov 12, 2014
  • USD 12800
  • 970 Pages

* 2014-2018 German Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing
  • Published:
  • Nov 12, 2014
  • USD 4300
  • 850 Pages

* 2014-2018 Japanese Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing
  • Published:
  • Nov 12, 2014
  • USD 5500
  • 860 Pages

* 2014-2018 US Infectious Disease Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
  • Published:
  • Nov 12, 2014
  • USD 3900
  • 636 Pages

* 2014-2018 US Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--Infectious Diseases, Genetic Diseases, Cancer, Forensic and Paternity Testing
  • Published:
  • Nov 12, 2014
  • USD 6200
  • 880 Pages

* 2014-2018 World Infectious Disease Molecular Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies
  • Published:
  • Nov 12, 2014
  • USD 12500
  • 775 Pages

* 2014-2018 World Molecular Diagnostics Market: Facilities, Test Volumes, and Sales Forecasts by Country
  • Published:
  • Nov 12, 2014
  • USD 2450
  • 15 Pages

* European Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies -Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics
  • Published:
  • Nov 11, 2014
  • USD 12900
  • 600 Pages

* Japanese Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies -Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics
  • Published:
  • Nov 11, 2014
  • USD 5700
  • 421 Pages

Browse more Biotechnology Equipment Market Research Reports

Pricing